Actavis Inc (ACT) 206.10 $ACT
Apple Among IBD's 5 'A-List' Big Cap Leaders
at Investor's Business Daily - Tue May 20, 6:03PM CDT
Apple (AAPL) is the coolest phone for A-listers. With earnings growth rebounding amid strong China demand, the tech titan is among five highly rated large-cap stocks that start with the letter A. IBD's Big Cap Leaders Screen of the Day lists large...
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - Sat May 17, 9:51AM CDT
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S....
Legal Setback for Eli Lilly in the UK - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 3:10PM CDT
Eli Lilly (LLY) received a legal setback on Alimta in the UK.
FDA Approvals, Stock Price Updates, and Financial Results Release - Analyst Notes on Pfizer, Actavis, Pharmacyclics, Mallinckrodt and Salix Pharmaceuticals
PR Newswire - Fri May 16, 6:40AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT), Pharmacyclics, Inc. (NASDAQ: PCYC), Mallinckrodt PLC (NYSE: MNK) and Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2541-100free.
Actavis signs agreement to extend distribution of JPI's Concerta
M2 - Thu May 15, 10:14AM CDT
Pharmaceutical company Actavis plc (NYSE:ACT) announced on Thursday that it has extended an agreement with Janssen Pharmaceuticals Inc (JPI) to supply the authorised generic version of JPI's Concerta (methylphenidate hydrochloride extended-release tablets).
Actavis Extends Exclusive Agreement to Distribute Authorized Generic Concerta®
PR Newswire - Thu May 15, 7:45AM CDT
Actavis plc (NYSE: ACT) today announced that it has reached an agreement with Janssen Pharmaceuticals, Inc. (JPI) to continue supplying the authorized generic version of JPI's Concerta® (methylphenidate hydrochloride extended-release tablets).
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Forest Laboratories Acquisition
PR Newswire - Wed May 14, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Laboratories, Inc., which is anticipated at mid-year. Following the close, Paul Bisaro, Chairman and Chief Executive Officer of Actavis, will become Executive Chairman. Brent Saunders, currently CEO and President of Forest, will become CEO and President, and a member of the Board of Directors. Robert Stewart, President, Actavis Global Operations, will become Chief Operating Officer. Mr. Saunders will report to Mr. Bisaro and the Board of Directors, and Mr. Stewart will report to Mr. Saunders.
Agreements, Earnings Releases, Senior-Level Retirements and Appointments, and Marketing Authorizations - Analyst Notes on Actavis, Jazz Pharmaceuticals, Bristol-Myers, Biogen Idec and AbbVie
PR Newswire - Wed May 14, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Bristol-Myers Squibb Company (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2434-100free.
Actavis Receives Final Approval for Generic Version of Exalgo®
PR Newswire - Tue May 13, 4:00PM CDT
Actavis plc (NYSE: ACT) today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Mallinckrodt Inc.'s Exalgo® (Hydromorphone Hydrochloride Extended-release Tablets 8 mg, 12 mg and 16 mg). Actavis intends to begin shipping its product shortly and believes that, under applicable Hatch Waxman rules, it may be entitled to marketing exclusivity.
Actavis to Present at Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014
PR Newswire - Tue May 13, 3:45PM CDT
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Paul Bisaro, Chairman and CEO of Actavis, will provide an overview and update of the Company's business at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 in New York City.
Actavis Announces Acanya® Gel Patent Challenge Settlement
PR Newswire - Mon May 12, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya® (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%. Acanya® Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris.
Technical Coverage on Pharma Equities -- Research on Allergan, Actavis, Medicines Co., and Akorn
PR Newswire - Fri May 09, 10:30AM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,550.97, and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished positive. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, and the index has advanced 0.78% in the last one month. Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Actavis PLC (NYSE: ACT), The Medicines Company (NASDAQ: MDCO) and Akorn Inc. (NASDAQ: AKRX). Free technical research on AGN, ACT, MDCO and AKRX can be downloaded upon signing up at:
Actavis Launches Generic Version of Catapres-TTS®
PR Newswire - Wed May 07, 3:05PM CDT
Actavis plc (NYSE: ACT) today announced that it has launched a generic version of Boehringer Ingelheim's Catapres-TTS® (Clonidine Transdermal System, USP, 0.1 mg/day, 0.2 mg/day, and 0.3 mg/day for one week), following the receipt of final approval on its Abbreviated New Drug Application from the U.S. Food and Drug Administration.
Acorda Misses on Earnings, Beats Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:43PM CDT
Acorda Therapeutics, Inc.'s (ACOR) first quarter earnings of 2 cents per share missed the Zacks Consensus Estimate of 4 cents.
What Does Celgene's May 15 Markman Hearing Mean to You?
at The Street - Wed May 07, 9:11AM CDT
Celgene faces a big hearing over patents on its franchise product. Here's what investors need to know.
Actavis, Michael Kors Among World Stocks Near Buy Points
at Investor's Business Daily - Tue May 06, 5:50PM CDT
Leading international stocks have proved highly resilient amid the market's correction. Two of IBD's current Top World Stocks, Ireland's Shire (SHPG) and Singapore-based Avago Technologies (AVGO), recently cleared buy points and moved to new highs....
Financial Results, Study Results, and Conference Schedules - Analyst Notes on Actavis, BMS, Baxter, Biogen Idec and AbbVie
PR Newswire - Tue May 06, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY), Baxter International Inc. (NYSE: BAX), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2075-100free.
Actavis and Forest Announce Effectiveness of Registration Statement on Form S-4
Business Wire - Mon May 05, 8:01AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission ("SEC"
by Actavis plc on March 25, 2014 and amended on May 2, 2014 (the "Form S-4" , which includes a joint proxy statement of Actavis and Forest, was declared effective on May 2, 2014. The Form S-4 is available on the SEC's EDGAR system, and may be accessed at https://www.sec.gov/Archives/edgar/data/15788...59ds4a.htm.
AstraZeneca Nixes New Bid As Pfizer Woos British PM
at Investor's Business Daily - Fri May 02, 1:11PM CDT
British big pharma AstraZeneca (AZN) turned down a second takeover bid from U.S. counterpart Pfizer (PFE) Friday, saying that the $106 billion offer was still too low. Pfizer's stock dropped nearly 2%, while AstraZeneca's held steady on the stock...
Apple Among IBD's 5 'A-List' Big Cap Leaders
at Investor's Business Daily - Tue May 20, 6:03PM CDT
Apple (AAPL) is the coolest phone for A-listers. With earnings growth rebounding amid strong China demand, the tech titan is among five highly rated large-cap stocks that start with the letter A. IBD's Big Cap Leaders Screen of the Day lists large...
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - Sat May 17, 9:51AM CDT
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S....
Legal Setback for Eli Lilly in the UK - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 3:10PM CDT
Eli Lilly (LLY) received a legal setback on Alimta in the UK.
FDA Approvals, Stock Price Updates, and Financial Results Release - Analyst Notes on Pfizer, Actavis, Pharmacyclics, Mallinckrodt and Salix Pharmaceuticals
PR Newswire - Fri May 16, 6:40AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT), Pharmacyclics, Inc. (NASDAQ: PCYC), Mallinckrodt PLC (NYSE: MNK) and Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2541-100free.
Actavis signs agreement to extend distribution of JPI's Concerta
M2 - Thu May 15, 10:14AM CDT
Pharmaceutical company Actavis plc (NYSE:ACT) announced on Thursday that it has extended an agreement with Janssen Pharmaceuticals Inc (JPI) to supply the authorised generic version of JPI's Concerta (methylphenidate hydrochloride extended-release tablets).
Actavis Extends Exclusive Agreement to Distribute Authorized Generic Concerta®
PR Newswire - Thu May 15, 7:45AM CDT
Actavis plc (NYSE: ACT) today announced that it has reached an agreement with Janssen Pharmaceuticals, Inc. (JPI) to continue supplying the authorized generic version of JPI's Concerta® (methylphenidate hydrochloride extended-release tablets).
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Forest Laboratories Acquisition
PR Newswire - Wed May 14, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Laboratories, Inc., which is anticipated at mid-year. Following the close, Paul Bisaro, Chairman and Chief Executive Officer of Actavis, will become Executive Chairman. Brent Saunders, currently CEO and President of Forest, will become CEO and President, and a member of the Board of Directors. Robert Stewart, President, Actavis Global Operations, will become Chief Operating Officer. Mr. Saunders will report to Mr. Bisaro and the Board of Directors, and Mr. Stewart will report to Mr. Saunders.
Agreements, Earnings Releases, Senior-Level Retirements and Appointments, and Marketing Authorizations - Analyst Notes on Actavis, Jazz Pharmaceuticals, Bristol-Myers, Biogen Idec and AbbVie
PR Newswire - Wed May 14, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Bristol-Myers Squibb Company (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2434-100free.
Actavis Receives Final Approval for Generic Version of Exalgo®
PR Newswire - Tue May 13, 4:00PM CDT
Actavis plc (NYSE: ACT) today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Mallinckrodt Inc.'s Exalgo® (Hydromorphone Hydrochloride Extended-release Tablets 8 mg, 12 mg and 16 mg). Actavis intends to begin shipping its product shortly and believes that, under applicable Hatch Waxman rules, it may be entitled to marketing exclusivity.
Actavis to Present at Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014
PR Newswire - Tue May 13, 3:45PM CDT
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Paul Bisaro, Chairman and CEO of Actavis, will provide an overview and update of the Company's business at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 in New York City.
Actavis Announces Acanya® Gel Patent Challenge Settlement
PR Newswire - Mon May 12, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya® (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%. Acanya® Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris.
Technical Coverage on Pharma Equities -- Research on Allergan, Actavis, Medicines Co., and Akorn
PR Newswire - Fri May 09, 10:30AM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,550.97, and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished positive. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, and the index has advanced 0.78% in the last one month. Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Actavis PLC (NYSE: ACT), The Medicines Company (NASDAQ: MDCO) and Akorn Inc. (NASDAQ: AKRX). Free technical research on AGN, ACT, MDCO and AKRX can be downloaded upon signing up at:
Actavis Launches Generic Version of Catapres-TTS®
PR Newswire - Wed May 07, 3:05PM CDT
Actavis plc (NYSE: ACT) today announced that it has launched a generic version of Boehringer Ingelheim's Catapres-TTS® (Clonidine Transdermal System, USP, 0.1 mg/day, 0.2 mg/day, and 0.3 mg/day for one week), following the receipt of final approval on its Abbreviated New Drug Application from the U.S. Food and Drug Administration.
Acorda Misses on Earnings, Beats Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 12:43PM CDT
Acorda Therapeutics, Inc.'s (ACOR) first quarter earnings of 2 cents per share missed the Zacks Consensus Estimate of 4 cents.
What Does Celgene's May 15 Markman Hearing Mean to You?
at The Street - Wed May 07, 9:11AM CDT
Celgene faces a big hearing over patents on its franchise product. Here's what investors need to know.
Actavis, Michael Kors Among World Stocks Near Buy Points
at Investor's Business Daily - Tue May 06, 5:50PM CDT
Leading international stocks have proved highly resilient amid the market's correction. Two of IBD's current Top World Stocks, Ireland's Shire (SHPG) and Singapore-based Avago Technologies (AVGO), recently cleared buy points and moved to new highs....
Financial Results, Study Results, and Conference Schedules - Analyst Notes on Actavis, BMS, Baxter, Biogen Idec and AbbVie
PR Newswire - Tue May 06, 8:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY), Baxter International Inc. (NYSE: BAX), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2075-100free.
Actavis and Forest Announce Effectiveness of Registration Statement on Form S-4
Business Wire - Mon May 05, 8:01AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission ("SEC"
by Actavis plc on March 25, 2014 and amended on May 2, 2014 (the "Form S-4" , which includes a joint proxy statement of Actavis and Forest, was declared effective on May 2, 2014. The Form S-4 is available on the SEC's EDGAR system, and may be accessed at https://www.sec.gov/Archives/edgar/data/15788...59ds4a.htm. AstraZeneca Nixes New Bid As Pfizer Woos British PM
at Investor's Business Daily - Fri May 02, 1:11PM CDT
British big pharma AstraZeneca (AZN) turned down a second takeover bid from U.S. counterpart Pfizer (PFE) Friday, saying that the $106 billion offer was still too low. Pfizer's stock dropped nearly 2%, while AstraZeneca's held steady on the stock...
